AAAAAA

   
Results: 1-11 |
Results: 11
Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Authors: Jung, LL Zamboni, WC
Citation: Ll. Jung et Wc. Zamboni, Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?, DRUG RESIST, 4(3), 2001, pp. 152-167
Pharmacodynamic model of topotecan-induced time course of neutropenia
Authors: Zamboni, WC D'Argenio, DZ Stewart, CF MacVittie, T Delauter, BJ Farese, AM Potter, DM Kubat, NM Tubergen, D Egorin, MJ
Citation: Wc. Zamboni et al., Pharmacodynamic model of topotecan-induced time course of neutropenia, CLIN CANC R, 7(8), 2001, pp. 2301-2308
The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid
Authors: Zamboni, WC Luftner, DI Egorin, MJ Schweigert, M Sezer, O Richter, T Natale, JJ Possinger, K
Citation: Wc. Zamboni et al., The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid, ANN ONCOL, 12(1), 2001, pp. 119-122
Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction
Authors: Herrington, JD Figueroa, JA Kirstein, MN Zamboni, WC Stewart, CF
Citation: Jd. Herrington et al., Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction, CANC CHEMOT, 47(1), 2001, pp. 89-93
Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan
Authors: Ma, MK Zamboni, WC Radomski, KM Furman, WL Santana, VM Houghton, PJ Hanna, SK Smith, AK Stewart, CF
Citation: Mk. Ma et al., Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan, CLIN CANC R, 6(3), 2000, pp. 813-819
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors
Authors: Zamboni, WC Egorin, MJ Van Echo, DA Day, RS Meisenberg, BR Brooks, SE Doyle, LA Nemieboka, NN Dobson, JM Tait, NS Tkaczuk, KH
Citation: Wc. Zamboni et al., Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors, J CL ONCOL, 18(18), 2000, pp. 3288-3294
Phase I study of docetaxel and topotecan in patients with solid tumors
Authors: Tkaczuk, KH Zamboni, WC Tait, NS Meisenberg, BR Doyle, LA Edelman, MJ Hausner, PF Egorin, MJ Van Echo, DA
Citation: Kh. Tkaczuk et al., Phase I study of docetaxel and topotecan in patients with solid tumors, CANC CHEMOT, 46(6), 2000, pp. 442-448
Pharmacokinetics of gemcitabine and 2 ',2 '-difluorodeoxyuridine in a patient with ascites
Authors: Delauter, BJ Ramanathan, RK Egorin, MJ Stover, LL Zuhowski, EG Plunkett, W Zamboni, WC
Citation: Bj. Delauter et al., Pharmacokinetics of gemcitabine and 2 ',2 '-difluorodeoxyuridine in a patient with ascites, PHARMACOTHE, 20(10), 2000, pp. 1204-1207
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
Authors: Furman, WL Stewart, CF Poquette, CA Pratt, CB Santana, VM Zamboni, WC Bowman, LC Ma, MK Hoffer, FA Meyer, WH Pappo, AS Walter, AW Houghton, PJ
Citation: Wl. Furman et al., Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children, J CL ONCOL, 17(6), 1999, pp. 1815-1824
Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors
Authors: Zamboni, WC Bowman, LC Tan, M Santana, VM Houghton, PJ Meyer, WH Pratt, CB Heideman, RL Gajjar, AJ Pappo, AS Stewart, CF
Citation: Wc. Zamboni et al., Interpatient variability in bioavailability of the intravenous formulationof topotecan given orally to children with recurrent solid tumors, CANC CHEMOT, 43(6), 1999, pp. 454-460
Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines
Authors: Zamboni, WC Houghton, PJ Hulstein, JL Kirstein, M Walsh, J Cheshire, PJ Hanna, SK Danks, MK Stewart, CF
Citation: Wc. Zamboni et al., Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines, CANC CHEMOT, 43(4), 1999, pp. 269-276
Risultati: 1-11 |